Co-venture: A Cluster Randomized Trial Investigating the Effects of Selective Intervention on Adolescent Cognitive Development and Addiction
The Preventure Program is the first and only school-based alcohol and drug prevention program that has been shown to prevent onset and growth in alcohol and substance misuse in British and Canadian youth. Unlike universal programs that tend to promote generic coping skills and balance normative attitudes around substance use, this selected personality-targeted approach is based on a psychosocial model and validated by Dr Patricia Conrod and targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity and Sensation Seeking, each associated with different motives for substance use, drug use profiles and patterns of non-addictive psychopathology. As a primary goal of the Coventure project, the investigators propose a long-term trial of this intervention strategy to examine how this evidence-based intervention can reduce onset of substance use disorders in young people and related secondary mental health, academic and cognitive outcomes. As a secondary goal, the investigators propose to use sensitive neuropsychological measures to examine how this evidence-based intervention can positively impact on cognitive development over the course of adolescence, to tease apart some of the mechanisms involved in the causal pathway from early onset substance use to poor cognitive development and long-term addiction outcomes.
NCT01655615 — Substance Related Disorders
Status: Active, not recruiting
http://inclinicaltrials.com/substance-related-disorders/NCT01655615/
Alcohol and TObacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support
This is a multicenter, interventional, randomized study for preventive and therapeutic strategies for patients with head and neck or Lung cancer; contribution of an addiction support
NCT01652456 — Lung Cancer
Status: Withdrawn
http://inclinicaltrials.com/lung-cancer/NCT01652456/
Pharmacologic MRI in Cocaine-addiction
In the proposed study, the investigators will assess the brain response to medication probes the investigators have previously studied with SPECT. The brain response to ondansetron and lidocaine infusions will be measured Arterial Spin Labeling and functional connectivity MRI (fcMRI).
NCT01652378 — Cocaine Dependence
Status: Completed
http://inclinicaltrials.com/cocaine-dependence/NCT01652378/
Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study
The treatment involves administering propranolol, a medication indicated for treating high blood pressure. Propranolol is hypothesized to reduce the strength of drug or alcohol cravings (an integral factor involved in relapse), specifically when memories of substance use are recalled. In this study, propranolol or a placebo will be administered to patients participating in a drug or alcohol rehabilitation facility once a week over three or six weeks. After receiving propranolol or placebo, strong memories associated with substance craving are recalled by asking participants to read aloud a summary of a substance use experience. The investigators hypothesize that participants who receive propranolol will report fewer and less intense drug or alcohol cravings than participants who receive the placebo or treatment-as-usual.
NCT01634347 — Substance Dependence
Status: Completed
http://inclinicaltrials.com/substance-dependence/NCT01634347/
Gene x Environment Interactions as Risk Factors for Addiction
Background: - The risk for becoming addicted to drugs varies among individual, even those using similar drugs in a similar way. It is not known why some people become addicted and others do not. Studies suggest that some genes may increase the risk of addiction. Negative life experiences may also affect the risk of addiction. Researchers want to test smokers and nonsmokers to study genetic and brain function traits that may lead to drug addiction. Objectives: - To understand brain function in people who may be at a higher risk of drug addiction. Eligibility: - Healthy volunteers between 18 and 55 years of age. - Smokers (10 to 30 cigarettes per day for more than 2 years) and nonsmokers will be eligible. Design: - Participants will be screened with a physical exam and medical history. They will be tested for drug and alcohol use. A blood sample will be collected. - The study will involve one visit. Participants will have a magnetic resonance imaging (MRI) scan. - At the visit, participants will answer questions about their health and drug use habits. They will then be trained on the tasks they will do during the MRI scan. After the training, they will have the scan and perform the tasks. The scan and tasks will look at brain function related to rewards and impulsiveness. - Other computer tests will be given after the scan. These tests will measure learning, memory, and impulsiveness.
NCT01621607 — Drug Addiction
Status: Completed
http://inclinicaltrials.com/drug-addiction/NCT01621607/
CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery - Prescription Opiates/Medication
The proposed project will use fMRI and specific probes of reward and inhibition as biomarkers predicting drug use during and after treatment in 72 subjects addicted to prescription opioids/medications. Subjects will be scanned before, during, and after 12 weeks of active medication. The brain fMRI measures will be correlated with the primary clinical outcome of drug use (by urine drug screen) during the treatment and follow-up phase.
NCT01587196 — Prescription Opiate/Medication Dependence
Status: Completed
http://inclinicaltrials.com/prescription-opiate-medication-dependence/NCT01587196/
A Pilot Study to Determine the Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction in Patients Treated for Pain Using a Comparative Transcriptomic Analysis of Gene Expression in Peripheral Blood Cells
This is a clinical study on patients who have been prescribed opioids (narcotic pain relievers) for the treatment of pain, to determine what genetic factors influence outcome of treatment. Procedures include: an initial telephone prescreening, completion of a number of questionnaires, and a blood draw to determine genetic factors. Participants will take part in a one-time clinic visit, during which all procedures will be completed. The investigators hypothesize that several classes of genes, including genes in opioid, pain, and reward pathways, will differentiate opioid-dependent subjects from opioid-exposed nondependent subjects.
NCT01562353 — Usage of Prescription Opioids
Status: Recruiting
http://inclinicaltrials.com/usage-of-prescription-opioids/NCT01562353/
Development of Induced Pluripotent Stem Cells Carrying Monoamine Transporter Polymorphisms
Background: - Researchers are interested in studying the roles that genes play in drug and alcohol addiction. Genes seem to account for about half of the differences between people who become addicted to drugs and people who do not. This study will collect blood and skin cell samples. These cells will be used to develop stem cells that are useful for studying how genes are related to drug use and dependence. Objectives: - To study genetic and cellular differences between people who are addicted to drugs and those who are not. Eligibility: - Individuals between 21 and 65 years of age who do not use drugs. - Individuals between 21 and 65 years of age who are in treatment with buprenorphine or methadone. Design: - Participants will be screened with a brief physical exam and medical history. - Participants will also answer questions about physical and mental health, quality of life, and history of drug and alcohol use. A urine sample and cheek swab sample will be collected. - Participants whose genetic samples match the study requirements will be asked to come back to provide a skin biopsy sample and a second urine sample.
NCT01534624 — Induced Pluripotent Stem Cells
Status: Completed
http://inclinicaltrials.com/induced-pluripotent-stem-cells/NCT01534624/
A Stage II Efficacy Study of Cognitive Behavioral Therapy for PTSD in Community Addiction Treatment
The purpose of this phase of the study is to assess the efficacy of CBT for PTSD, as delivered by routine addiction counselors in community treatment programs, and to compare CBT for PTSD with both Individual Addiction Counseling (IAC) and Treatment as Usual (TAU) on the primary outcomes.
NCT01457391 — Substance-Related Disorders
Status: Completed
http://inclinicaltrials.com/substance-related-disorders/NCT01457391/
Cognitive Behavioral Therapy for PTSD in Addiction Treatment: A Randomized Pilot Trial
The purpose of this phase of the study is to further assess the efficacy of cognitive behavioral therapy (CBT) for posttraumatic stress disorder (PTSD), as delivered by routine addiction counselors, and to compare CBT for PTSD with individual addiction counseling (IAC) on our primary outcomes.
NCT01456338 — Substance-Related Disorders
Status: Completed
http://inclinicaltrials.com/substance-related-disorders/NCT01456338/